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Appendix 1
Which methods are used to confirm the diagnosis 
of acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Karyotyping, cytogenetics, flow cytometry, fluorescence in situ 
hybridization, reverse transcriptase polymerase chain reaction or 
morphology of bone marrow cells
O – Diagnosis
Acute promyelocytic leukemia AND (Differential diagnosis 
OR Flow cytometry OR karyotyping OR Cytogenetic Analysis 
OR Fluorescence in situ hybridization OR Polymerase chain 
reaction OR bone marrow examination OR electrophoresis 
OR monoclonal OR immunofixation OR light chain OR 
immunoglobulin OR symptoms OR anemia OR fractures OR bone 
lesions OR hypercalcemia OR renal failure OR renal insufficiency 
OR clinical chemistry tests OR cytodiagnosis OR hematologic 
tests OR immunologic tests) AND (Diagnosis/Narrow) = 89
1st selection: 27
2nd selection: 6
Which laboratory tests are used to evaluate 
coagulopathies in acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Coagulogram, D-Dimer, fibrinogen, platelets, prothrombin time, 
activated partial thromboplastin time, fibrin degradation products
O – Bleeding
Acute promyelocytic leukemia AND (blood coagulation disorders 
OR hemorrhage OR bleeding) AND (fibrinogen degradation 
products OR D-dimer OR fibrinogen OR blood platelets OR blood 
coagulation tests) = 143
1st selection: 5
How can the risk of relapse of patients with acute 
promyelocytic leukemia be stratified?
P – Acute promyelocytic leukemia
I – Risk stratification
O – Recurrence
Leukemia, Promyelocytic, Acute AND Risk AND (Treatment 
Failure OR Recurrence) = 123
1st selection: 4
How should coagulopathies in acute 
promyelocytic leukemia be treated?
P – Acute promyelocytic leukemia
I – Coagulopathy
O – Treatment
Acute promyelocytic leukemia AND (blood coagulation 
disorders) AND (Therapy/Broad[filter]) = 153
1st selection: 38
2nd selection: 11
Which anthracycline should be used in induction 
therapy for acute promyelocytic leukemia, in 
terms of response rate, overall survival and 
toxicity?
P – Acute promyelocytic leukemia
I – Anthracycline (daunorubicin, doxorubicin, idarubicin or 
mitoxantrone)
O - Response rate, overall survival and toxicity
Acute promyelocytic leukemia AND (Daunorubicin OR 
Doxorubicin OR Idarubicin OR Cytarabine OR Mitoxantrone) AND 
(Therapy/broad[filter] OR Comparative study OR Comparative 
studies OR Epidemiologic methods)) = 664
1st selection: 38
2nd selection: 8
Is induction with arsenic trioxide superior 
to induction with all-trans retinoic acid plus 
anthracycline?
P – Acute promyelocytic leukemia
I – Arsenic trioxide or arsenicals
C – All-trans retinoic acid
Acute promyelocytic leukemia AND (arsenic trioxide OR 
arsenicals) AND (tretinoin) AND (Therapy/Narrow) = 6
1st selection: 2
What are the risk factors for the development of 
differentiation syndrome?
P – Acute promyelocytic leukemia
I – Risk factors
O – Differentiation syndrome
Acute promyelocytic leukemia AND (tretinoin* OR ATRA 
OR ATRA-syndrome OR ATRA syndrome OR retinoic acid 
differentiation syndrome OR retinoic acid syndrome OR 
differentiation syndrome) AND risk =231
1st selection: 7
Is the prophylactic use of corticosteroids in 
patients with acute promyelocytic leukemia able 
to prevent Differentiation syndrome?
P – Acute promyelocytic leukemia/Differentiation syndrome
I – Corticosteroid, prophylaxis
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C – All-trans retinoic acid
O – Prevent Differentiation syndrome
Acute promyelocytic leukemia AND steroids AND tretinoin =191
1st selection: 4
What is the best therapeutic conduct for 
Differentiation syndrome?
P – Differentiation syndrome
I – Corticosteroid, diuretics, interruption of ATRA
O – Improvement in symptoms
Acute promyelocytic leukemia AND tretinoin =2320
1st selection: 29
What is the best therapeutic conduct for 
pseudotumor cerebri syndrome?
P - Pseudotumor cerebri syndrome in patients with acute 
promyelocytic leukemia
I - Corticoid
Acute promyelocytic leukemia AND (pseudotumor cerebri) AND 
(Therapy/Broad) = 31
1st selection: 21
Is prophylaxis of the central nervous system 
indicated for a specific group of patients with 
acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Methotrexate or cytarabine
O – Prophylaxis of the central nervous system
Acute promyelocytic leukemia AND (methotrexato OR 
cytarabine) AND (meningitis OR central nervous system 
infections OR liquor OR infiltrating) = 2
1st selection: 2
Are there benefits with the use of cytarabine in 
acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Cytarabine
O – Complete remission, disease-free survival, overall survival
Acute promyelocytic leukemia AND (Cytarabine) AND (Therapy/
broad[filter] OR Comparative study OR Comparative studies OR 
Epidemiologic methods)) = 401
1st selection: 9
What is the role of transplantation in relapse 
of acute promyelocytic leukemia and when 
should allogeneic and autologous transplants be 
indicated?
P – Acute promyelocytic leukemia
I – Allogeneic transplant 
C – Autologous transplant
O – Complete remission, disease-free survival, overall survival
Acute promyelocytic leukemia AND (transplantation OR 
transplant) AND allogeneic AND autologous AND (Therapy/
Broad) = 46
1st selection: 3
How to make the diagnosis of molecular 
relapse? Which method, quantitative or 
qualitative polymerase chain reaction, is most 
recommended?
P – Acute promyelocytic leukemia
I – Quantitative polymerase chain reaction, 
C – Qualitative polymerase chain reaction
O – Molecular relapse
Acute promyelocytic leukemia AND (polymerase chain 
reaction) AND (quantitative OR qualitative) AND (recurrence OR 
remission) = 42
Acute promyelocytic leukemia AND Reverse Transcriptase 
Polymerase Chain Reaction AND (recurrence OR remission) =163
1st selection: 6
What are the best therapeutic options for 
hematologic and extramedullary relapse?
P – Relapse or recurrence and acute promyelocytic leukemia
I – All-trans retinoic acid or arsenic trioxide or systemic 
chemotherapy
O – Remission
Acute promyelocytic leukemia AND (recurrence OR remission) 
AND (Therapy/Narrow) = 56
1st selection: 5
How should the patient with acute promyelocytic 
leukemia during pregnancy be treated?
P – Pregnant women with acute promyelocytic leukemia
I – All-trans retinoic acid or cytarabine or anthracycline 
(daunorubicin or idarubicin)
O – Complete remission, disease-free survival, overall survival
Acute promyelocytic leukemia AND pregnancy AND (Therapy/
Broad[filter]) = 58
1st selection: 26
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How should an elderly patient with acute 
promyelocytic leukemia be treated?
P – Acute promyelocytic leukemia, elderly
I – All-trans retinoic acid or cytarabine or anthracycline (idarubicin 
or daunorubicin)
O – Complete remission, disease-free survival, overall survival
Acute promyelocytic leukemia AND age AND (tretinoin OR 
Cytarabine OR Idarubicin OR daunorubicin) = 719
1st selection: 5
How should minimal residual disease in acute 
promyelocytic leukemia be monitored?
P – Acute promyelocytic leukemia
I – Polymerase chain reaction
O – Minimal residual disease
Acute promyelocytic leukemia AND neoplasm residual = 272
1st selection: 7
